RxDoctor Payments Data

Jennifer McWilliams

Acute Care · Halls, TNNPI 1720289143

Payments from drug & device makers

$2,934in general payments, 2019–2025

Across 200 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$772
  • AbbVie$743
  • AstraZeneca$450
  • Amgen$145
  • GSK$128
  • Biohaven Pharmaceutical Holding Company Ltd.$122
  • plus $574 from 12 others

What the payments were for

  • Food & beverage$2,934100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,934 in reported general payments places this provider in the 85th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$71,208
Medicare patients
242
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$146,838
FarxigaDapagliflozin Propanediol142$100,032
MounjaroTirzepatide85$89,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$76,404
EliquisApixaban58$46,981
JardianceEmpagliflozin72$45,133
TradjentaLinagliptin54$43,241
LinzessLinaclotide64$41,642
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$24,835
TrulicityDulaglutide16$20,050
XareltoRivaroxaban32$19,038
Repatha SureclickEvolocumab17$11,267
Bydureon BciseExenatide Microspheres13$10,074
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,491
Breo ElliptaFluticasone/Vilanterol16$6,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$772$146,838137 claims
AstraZenecaFarxiga, Breztri Aerosphere$450$124,867179 claims
Lilly USA, LLCMounjaro, Trulicity$52$110,045101 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$128$90,006146 claims
PfizerEliquis, Abrysvo$96$50,63670 claims
AbbVieLinzess, Synthroid$743$43,29287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 738 acute care providers in Tennessee.

Other acute care in Halls

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →